FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

GILLIS STEVEN 		2. Issuer Name and Ticker or Trading Symbol

Trubion Pharmaceuticals, Inc [ TRBN ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
__ X __ Officer (give title below)      __ X __ Other (specify below)
Ex. Chair. & President / 10% Owner Indirect
(Last)          (First)          (Middle)

ARCH VENTURE PARTNERS, 1000 2ND AVENUE, SUITE 3700 		3. Date of Earliest Transaction (MM/DD/YYYY)

10/28/2010
(Street)

SEATTLE, WA 98104
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   10/28/2010     D    2357046   D   (1) 0   I   By ARCH entities   (2)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock option (right to buy)   $6.52   10/28/2010     D         19135      (3) 3/8/2016   Common stock   19135   $0.00   0   D    
Stock option (right to buy)   $19.08   10/28/2010     D         5000      (4) 5/25/2017   Common stock   5000   $0.00   0   D    
Stock option (right to buy)   $6.63   10/28/2010     D         5000      (5) 5/28/2018   Common stock   5000   $0.00   0   D    
Stock option (right to buy)   $2.28   10/28/2010     D         5000      (6) 5/27/2019   Common stock   5000   $0.00   0   D    
Stock option (right to buy)   $4.13   10/28/2010     D         90000      (7) 11/16/2019   Common stock   90000   $0.00   0   D    

Explanation of Responses:
( 1)  Disposed of pursuant to merger agreement among the issuer and Emergent BioSolutions Inc., and certain of its affiliates, in exchange for (a) an aggregate of $3,217,367.79 cash, (b) 386,791 shares of Emergent common stock having a market value of $18.26 per share on the effective date of the merger and (c) 2,357,046 contingent value rights, which represent the right to receive possible additional cash payments.
( 2)  Represents (a) 2,209,741 shares held by ARCH Venture Fund V, L.P., (b) 132,802 shares held by Healthcare Focus Fund, L.P. and (c) 14,503 shares held by ARCH V Entrepreneurs Fund, L.P. (together, the "ARCH Entities"). The reporting person, in addition to being an employee of the issuer, is also an employee of ARCH Venture Corporation, a service provider to the ARCH Entities. The reporting person disclaims beneficial ownership of the shares held by each of the ARCH Entities, except to the extent of his proportionate pecuniary partnership interest in ARCH Venture Fund V, L.P.
( 3)  This option, which was 100% vested on January 25, 2010, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received.
( 4)  This option, which was 100% vested on May 27, 2008, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received.
( 5)  This option, which was 100% vested on May 15, 2009, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates, without any consideration being received.
( 6)  This option, which was 100% vested on May 26, 2010, was cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $11,350, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 5,000 contingent value rights, which represents the right to receive possible additional future cash payments.
( 7)  This option, which provided for vesting at the rate of 1/36th on December 16, 2009, and then 1/36th monthly thereafter, such that all of the shares would be fully vested as of November 16, 2012, was vested in its entirety and then cancelled in the merger between the issuer and Emergent BioSolutions Inc. and certain of its affiliates in exchange for (a) a cash payment of $37,800, representing the difference between the exercise price and the initial merger consideration of $4.55 per share, and (b) 90,000 contingent value rights, which represents the right to receive possible additional future cash payments.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
GILLIS STEVEN
ARCH VENTURE PARTNERS
1000 2ND AVENUE, SUITE 3700
SEATTLE, WA 98104 		X
Ex. Chair. & President 10% Owner Indirect

Signatures
/s/ Kathleen Deeley as attorney-in-fact for Steven Gillis 10/28/2010
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Trubion Pharmaceuticals (MM) (NASDAQ:TRBN)
過去 株価チャート
から 5 2024 まで 6 2024 Trubion Pharmaceuticals (MM)のチャートをもっと見るにはこちらをクリック
Trubion Pharmaceuticals (MM) (NASDAQ:TRBN)
過去 株価チャート
から 6 2023 まで 6 2024 Trubion Pharmaceuticals (MM)のチャートをもっと見るにはこちらをクリック